PB 84 of 2024
National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 4) 2024
I, Nikolai Tsyganov, as delegate of the Minister for Health and Aged Care, make the following Determination.
Dated 23 October 2024
Nikolai Tsyganov
Assistant Secretary
Pricing and PBS Policy Branch
Technology Assessment and Access Division
Department of Health and Aged Care
Contents
1 Name
2 Commencement
3 Authority
4 Schedules
Schedule 1—Amendments—General
National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023
Schedule 2—Amendments— Additional designated brands effective from 1 February 2025
National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023
Schedule 3—Amendments— Additional designated brands effective from 1 April 2025
National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023
(1) This instrument is the National Health (Floor Price for Certain Brands of Pharmaceutical Items) Amendment Determination (No. 4) 2024.
(2) This instrument may also be cited as PB 84 of 2024.
(1) Each provision of this instrument specified in column 1 of the table commences, or is taken to have commenced, in accordance with column 2 of the table. Any other statement in column 2 has effect according to its terms.
Commencement information | ||
Column 1 | Column 2 | Column 3 |
Provisions | Commencement | Date/Details |
1. Sections 1 to 4 and anything in this instrument not elsewhere covered by this table | The day after this instrument is registered. |
|
2. Schedule 1 | The day after this instrument is registered. |
|
3. Schedule 2 | 1 February 2025. | 1 February 2025 |
4. Schedule 3 | 1 April 2025. | 1 April 2025 |
Note: This table relates only to the provisions of this instrument as originally made. It will not be amended to deal with any later amendments of this instrument.
(2) Any information in column 3 of the table is not part of this instrument. Information may be inserted in this column, or information in it may be edited, in any published version of this instrument.
This instrument is made under subsection 99ADHC(2) of the National Health Act 1953.
Each instrument that is specified in a Schedule to this instrument is amended or repealed as set out in the applicable items in the Schedule concerned, and any other item in a Schedule to this instrument has effect according to its terms.
National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023
1 Section 5 (table)
Omit:
Diltiazem AN | Diltiazem | Tablet containing diltiazem hydrochloride 60 mg | Oral |
Schedule 2—Amendments— Additional designated brands effective from 1 February 2025
National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023
1 Section 5 (after table item dealing with the brand Isoleucine 50 of the drug Isoleucine with carbohydrate in the form Sachets of oral powder 4 g containing 50 mg isoleucine, 30 (Isoleucine 50))
Insert:
APO-Levetiracetam | Levetiracetam | Oral solution 100 mg per mL, 300 mL | Oral |
Keppra | Levetiracetam | Oral solution 100 mg per mL, 300 mL | Oral |
Kerron | Levetiracetam | Oral solution 100 mg per mL, 300 mL | Oral |
Levetiracetam GH | Levetiracetam | Oral solution 100 mg per mL, 300 mL | Oral |
Levetiracetam-AFT | Levetiracetam | Oral solution 100 mg per mL, 300 mL | Oral |
APO-Levetiracetam | Levetiracetam | Tablet 1 g | Oral |
Keppra | Levetiracetam | Tablet 1 g | Oral |
Kevtam 1000 | Levetiracetam | Tablet 1 g | Oral |
Levactam | Levetiracetam | Tablet 1 g | Oral |
Levetiracetam GH | Levetiracetam | Tablet 1 g | Oral |
Levetiracetam Mylan | Levetiracetam | Tablet 1 g | Oral |
Levetiracetam SZ | Levetiracetam | Tablet 1 g | Oral |
Levetiracetam Viatris | Levetiracetam | Tablet 1 g | Oral |
Levi 1000 | Levetiracetam | Tablet 1 g | Oral |
NOUMED LEVETIRACETAM | Levetiracetam | Tablet 1 g | Oral |
Schedule 3—Amendments— Additional designated brands effective from 1 April 2025
National Health (Floor Price for Certain Brands of Pharmaceutical Items) Determination 2023
1 Section 5 (before table item dealing with the brand GA gel of the drug Amino acid formula with vitamins and minerals without lysine and low in tryptophan in the form Sachets containing oral powder 24 g, 30 (GA gel))
Insert:
Fosamax Plus 70 mg/140 mcg | Alendronic acid with colecalciferol | Tablet 70 mg (as alendronate sodium) with 140 micrograms colecalciferol | Oral |
Fosamax Plus | Alendronic acid with colecalciferol | Tablet 70 mg (as alendronate sodium) with 70 micrograms colecalciferol | Oral |
2 Section 5 (after table item dealing with the brand Kineret of the drug Anakinra in the form Injection 100 mg in 0.67 mL single use pre-filled syringe)
Insert:
Atropine Injection (Pfizer) | Atropine | Injection containing atropine sulfate monohydrate 600 micrograms in 1 mL | Injection |
Colazide | Balsalazide | Capsule containing balsalazide sodium 750 mg | Oral |
3 Section 5 (after table item dealing with the brand Bicillin L-A of the drug Benzathine benzylpenicillin in the form Injection containing 600,000 units benzathine benzylpenicillin tetrahydrate in 1.17 mL single use pre-filled syringe)
Insert:
Lax-Tab | Bisacodyl | Tablet 5 mg | Oral |
4 Section 5 (after table item dealing with the brand Pulmicort Turbuhaler of the drug Budesonide in the form Powder for oral inhalation in breath actuated device 200 micrograms per dose, 200 doses)
Insert:
Calci-Tab 600 | Calcium | Tablet 600 mg (as carbonate) | Oral |
5 Section 5 (after table item dealing with the brand Triumeq of the drug Dolutegravir with abacavir and lamivudine in the form Tablet containing dolutegravir 50 mg with abacavir 600 mg and lamivudine 300 mg)
Insert:
Mayne Pharma Erythromycin | Erythromycin | capsule 250 mg (containing enteric coated pellets) | Oral |
6 Section 5 (after table item dealing with the brand Estraderm MX 25 of the drug Estradiol in the form Transdermal patches 750 micrograms (as hemihydrate), 8)
Insert:
Ferro-Liquid | Ferrous Sulfate | Oral liquid containing 30 mg ferrous sulfate heptahydrate per mL, 250 mL | Oral |
7 Section 5 (after table item dealing with the brand Flucil of the drug Flucloxacillin in the form Powder for oral liquid 250 mg (as sodium monohydrate) per 5 mL, 100 mL)
Insert:
Lasix | Furosemide | Oral solution 10 mg per ml, 30 ml | Oral |
8 Section 5 (after table item dealing with the brand Fucidin of the drug Fusidic acid in the form Tablet containing sodium fusidate 250 mg)
Insert:
Nitrolingual Pumpspray | Glyceryl trinitrate | Sublingual spray (pump pack) 400 micrograms per dose, 200 doses | Sublingual |
9 Section 5 (after table item dealing with the brand Isoleucine 50 of the drug Isoleucine with carbohydrate in the form Sachets of oral powder 4 g containing 50 mg isoleucine, 30 (Isoleucine 50)
Insert:
Presolol 100 | Labetalol | Tablet containing labetalol hydrochloride 100 mg | Oral |
10 Section 5 (after table item dealing with the brand MORPHINE SULFATE 30 mg/1 mL MEDSURGE of the drug Morphine in the form Injection containing morphine sulfate pentahydrate 30 mg in 1 mL)
Insert:
Norimin-1 28 Day | Norethisterone with ethinylestradiol | Pack containing 21 tablets 1 mg-35 micrograms and 7 inert tablets | Oral |
Norimin 28 Day | Norethisterone with ethinylestradiol | Pack containing 21 tablets 500 micrograms-35 micrograms and 7 inert tablets | Oral |
11 Section 5 (after table item dealing with the brand Lipistart of the drug Triglycerides - medium chain, formula in the form Oral powder 400 g (Lipistart))
Insert:
MCT Oil | Triglycerides, medium chain | Oil 500 ml (MCT Oil) | Oral |